# OnCo record pembrolizumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pembrolizumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pembrolizumab" ;
  schema:name "Pembrolizumab"@en ;
  schema:description "Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines."@en ;
  schema:url <https://onco.cc/drugs/pembrolizumab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pembrolizumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q13896859> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pembrolizumab>, <https://www.nice.org.uk/guidance/ta851>, <https://www.nice.org.uk/guidance/ta801>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22KEYTRUDA%22>, <https://www.nice.org.uk/guidance/ta914>, <https://www.nice.org.uk/guidance/ta709>, <https://www.nice.org.uk/guidance/ta531>, <https://www.nice.org.uk/guidance/ta683>, <https://www.nice.org.uk/guidance/ta770>, <https://www.nice.org.uk/guidance/ta1017>, <https://www.nice.org.uk/guidance/ta1037> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-PD-1)" ;
  schema:alternateName "Keytruda / Keytruda Qlex (SC)" ;
  onco:approval "US 2014: Melanoma (first of >40 indications)", "US 2017: MSI-H/dMMR solid tumours (tumour-agnostic)", "US 2020: Metastatic TNBC, PD-L1 CPS ≥10, with chemotherapy", "US 2021: High-risk early TNBC, neoadjuvant + adjuvant (KEYNOTE-522)", "US 2023: Locally advanced unresectable or metastatic biliary tract cancer (gallbladder cancer included) with gemcitabine and cisplatin (KEYNOTE-966)", "US 2026: Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC", "EU 2021: Locally recurrent unresectable or metastatic TNBC, PD-L1 CPS 10 or more, with chemotherapy, no prior chemotherapy for metastatic disease (KEYNOTE-355)", "EU 2022: Locally advanced or early-stage TNBC at high risk of recurrence: neoadjuvant with chemotherapy, then adjuvant monotherapy (KEYNOTE-522)", "UK 2022: Untreated triple-negative locally recurrent unresectable or metastatic breast cancer with paclitaxel or nab-paclitaxel; NICE TA801 (29 June 2022) recommends it only for tumours with CPS 10 or more and immune-cell staining below 1 percent (the atezolizumab population is carved out), under a commercial arrangement", "UK 2022: Neoadjuvant with chemotherapy then adjuvant alone for triple-negative early breast cancer at high risk of recurrence or locally advanced disease; NICE TA851 (14 December 2022) recommends within the marketing authorisation, routine commissioning with a commercial arrangement", "UK 2023: Mismatch repair deficient or MSI-high tumours: NICE TA914 (20 September 2023) covers previously treated endometrial, gastric, small intestine, biliary and colorectal cancer and does not include pancreatic cancer", "England (NICE) 2021: Untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency", "England (NICE) 2023: Previously treated MSI-high or dMMR endometrial, biliary, colorectal, gastric or small intestine cancer", "England (NICE) 2018: Untreated PD-L1-positive metastatic non-small-cell lung cancer with a tumour proportion score of 50 percent or more and no EGFR or ALK alteration", "England (NICE) 2021: Untreated metastatic non-squamous non-small-cell lung cancer without an EGFR or ALK alteration, with pemetrexed and platinum chemotherapy", "England (NICE) 2022: Untreated metastatic squamous non-small-cell lung cancer, with carboplatin and paclitaxel", "England (NICE) 2017: Locally advanced or metastatic PD-L1-positive non-small-cell lung cancer after at least one chemotherapy", "England (NICE) 2024: Resectable non-small-cell lung cancer at high risk of recurrence, neoadjuvant with platinum chemotherapy then adjuvant alone", "England (NICE) 2025: Adjuvant treatment of non-small-cell lung cancer at high risk of recurrence after complete resection and platinum chemotherapy" ;
  onco:acceleratedApproval "US 2014-09-04: Unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor", "US 2015-10-02: Metastatic PD-L1 positive NSCLC, as determined by an FDA-approved test, with progression on or after platinum-containing chemotherapy", "US 2016-08-05: Recurrent or metastatic head and neck squamous cell carcinoma that progressed on or after platinum-containing chemotherapy", "US 2017-03-14: Adult and pediatric patients with refractory classical Hodgkin Lymphoma or who have relapsed after 3 or more prior lines of therapy", "US 2017-05-10: In combination with pemetrexed and carboplatin for first-line treatment of metastatic non-squamous NSCLC", "US 2017-05-18: Locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy 1", "US 2017-05-23: Treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, or metastatic MSI-H or dMMR colorectal cancer that have progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan", "US 2017-09-22: For patients with recurrent or locally advanced or metastatic gastric or GEJ adenocarcinoma whose tumors express PD-L1 [CPS ≥1] as determined by an FDA-approved test, with disease progression on/after two or more prior lines of therapy including fluoropyrimidine and platinum containing chemotherapy and if appropriate, HER2/NEU targeted therapy", "US 2018-06-12: Treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >/=1) as determined by an FDA approved test", "US 2018-06-13: Adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or who have relapsed after 2 or more prior lines of therapy", "US 2018-11-09: Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib", "US 2018-12-19: Treatment of adults and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)", "US 2019-06-17: Metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy", "US 2019-09-17: In combination with lenvatinib for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation", "US 2020-04-28: Dosing Regimen: Alternative dose/schedule of 400mg every 6 weeks for adult patients with melanoma, hepatocellular carcinoma, Merkel cell carcinoma, gastric cancer, non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, cervical carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, small cell lung cancer, esophageal cancer, microsatellite instability-high or mismatch repair deficient solid tumors", "US 2020-04-28: Dosing Regimen: Alternative dose/schedule of 400 mg every 6 weeks for adult patients with classical Hodgkin lymphoma and primary mediastinal b-cell lymphoma", "US 2020-06-16: Treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden high (TMB H) [=10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options .", "US 2020-06-16: Dosing Regimen: Alternate Dose/Schedule of 400 mg every 6 weeks for adult patients with unresectable or metastatic tumor mutational burden high [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options", "US 2020-06-24: Dosing Regimen: Alternative dose/schedule of 400mg every 6 weeks for adult patients with cutaneous squamous cell carcinoma", "US 2020-11-13: In combination with chemotherapy for locally recurrent unresectable or metastatic TNBC expressing PD L1 [CPS =10] as determined by an FDA-approved test", "US 2021-05-05: In combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma 1", "US 2023-04-03: In combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy", "US 2025-09-19: Formulation: Treatment of adult and pediatric patients 12 years and older with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options ." ;
  onco:acceleratedApprovalConfirmed "US 2015-12-18: Unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor", "US 2016-10-24: Metastatic PD-L1 positive NSCLC, as determined by an FDA-approved test, with progression on or after platinum-containing chemotherapy", "US 2018-08-20: In combination with pemetrexed and carboplatin for first-line treatment of metastatic non-squamous NSCLC", "US 2019-06-10: Recurrent or metastatic head and neck squamous cell carcinoma that progressed on or after platinum-containing chemotherapy", "US 2020-10-14: Adult and pediatric patients with refractory classical Hodgkin Lymphoma or who have relapsed after 3 or more prior lines of therapy", "US 2020-10-14: Adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or who have relapsed after 2 or more prior lines of therapy", "US 2021-07-21: In combination with lenvatinib for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation", "US 2021-07-26: In combination with chemotherapy for locally recurrent unresectable or metastatic TNBC expressing PD L1 [CPS =10] as determined by an FDA-approved test", "US 2021-08-31: Locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy 1", "US 2021-10-13: Treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >/=1) as determined by an FDA approved test", "US 2022-12-16: Dosing Regimen: Alternative dose/schedule of 400mg every 6 weeks for adult patients with melanoma, hepatocellular carcinoma, Merkel cell carcinoma, gastric cancer, non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, cervical carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, small cell lung cancer, esophageal cancer, microsatellite instability-high or mismatch repair deficient solid tumors", "US 2022-12-16: Dosing Regimen: Alternate Dose/Schedule of 400 mg every 6 weeks for adult patients with unresectable or metastatic tumor mutational burden high [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options", "US 2022-12-16: Dosing Regimen: Alternative dose/schedule of 400mg every 6 weeks for adult patients with cutaneous squamous cell carcinoma", "US 2023-03-28: Treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, or metastatic MSI-H or dMMR colorectal cancer that have progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan", "US 2023-10-12: Treatment of adults and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)", "US 2023-12-15: In combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy", "US 2024-01-25: Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib", "US 2025-03-19: In combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma 1" ;
  onco:related <https://onco.cc/technologies/tmb-testing/>, <https://onco.cc/biomarkers/pd-l1-cps/>, <https://onco.cc/biomarkers/pd-l1-tps/>, <https://onco.cc/biomarkers/dmmr-ihc/>, <https://onco.cc/biomarkers/msi-high/>, <https://onco.cc/biomarkers/tmb-high/> ;
  onco:cancers <https://onco.cc/cancers/msi-high-pdac/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/recurrent-metastatic-hnscc/>, <https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/gastric-pdl1-high/>, <https://onco.cc/cancers/gastric-msi-high/>, <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/msi-high-colorectal/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/tnbc-early/>, <https://onco.cc/cancers/tnbc-metastatic/>, <https://onco.cc/cancers/pdl1-high-nsclc/>, <https://onco.cc/cancers/resectable-nsclc/>, <https://onco.cc/cancers/advanced-melanoma/>, <https://onco.cc/cancers/stage-iii-melanoma/>, <https://onco.cc/cancers/stage-ii-melanoma/>, <https://onco.cc/cancers/advanced-cutaneous-scc/>, <https://onco.cc/cancers/merkel-cell-carcinoma/>, <https://onco.cc/cancers/endometrial-mmr-deficient/>, <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/>, <https://onco.cc/cancers/locally-advanced-cervical-cancer/>, <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/>, <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/>, <https://onco.cc/cancers/vaginal-adenocarcinoma/>, <https://onco.cc/cancers/advanced-small-bowel-adenocarcinoma/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:trials <https://onco.cc/trials/keynote-522/>, <https://onco.cc/trials/keynote-355/>, <https://onco.cc/trials/ascent-04/>, <https://onco.cc/trials/interpath-001/>, <https://onco.cc/trials/nct06212752/>, <https://onco.cc/trials/nct06348199/>, <https://onco.cc/trials/nct06758401/>, <https://onco.cc/trials/nct06216301/>, <https://onco.cc/trials/nct05920356/>, <https://onco.cc/trials/nct06430866/>, <https://onco.cc/trials/nct06692738/>, <https://onco.cc/trials/nct06448312/>, <https://onco.cc/trials/nct06899126/>, <https://onco.cc/trials/nct06698042/>, <https://onco.cc/trials/nct07216703/>, <https://onco.cc/trials/nct06699212/>, <https://onco.cc/trials/nct05727904/>, <https://onco.cc/trials/nct04613596/>, <https://onco.cc/trials/nct07541170/>, <https://onco.cc/trials/nct07361510/>, <https://onco.cc/trials/nct06170788/>, <https://onco.cc/trials/nct06452277/>, <https://onco.cc/trials/nct06311721/>, <https://onco.cc/trials/nct06989112/>, <https://onco.cc/trials/nct06422143/>, <https://onco.cc/trials/nct05215340/>, <https://onco.cc/trials/nct05317858/>, <https://onco.cc/trials/nct06711900/>, <https://onco.cc/trials/nct06712316/>, <https://onco.cc/trials/nct06312137/>, <https://onco.cc/trials/nct05608291/>, <https://onco.cc/trials/nct06947928/>, <https://onco.cc/trials/nct06952504/>, <https://onco.cc/trials/nct05555732/>, <https://onco.cc/trials/nct06077760/>, <https://onco.cc/trials/nct06726265/>, <https://onco.cc/trials/nct02362594/>, <https://onco.cc/trials/nct06561386/>, <https://onco.cc/trials/nct04624204/>, <https://onco.cc/trials/nct06767514/>, <https://onco.cc/trials/nct05722015/>, <https://onco.cc/trials/nct06793215/>, <https://onco.cc/trials/nct06357533/>, <https://onco.cc/trials/nct05048797/>, <https://onco.cc/trials/nct06627647/>, <https://onco.cc/trials/nct05549297/>, <https://onco.cc/trials/nct04657991/>, <https://onco.cc/trials/nct04956692/>, <https://onco.cc/trials/nct05984277/>, <https://onco.cc/trials/nct07777822/>, <https://onco.cc/trials/nct07178795/>, <https://onco.cc/trials/nct07195695/>, <https://onco.cc/trials/nct05987332/>, <https://onco.cc/trials/nct03556228/>, <https://onco.cc/trials/nct05180799/>, <https://onco.cc/trials/nct05446298/>, <https://onco.cc/trials/nct05784688/>, <https://onco.cc/trials/nct03970746/>, <https://onco.cc/trials/nct02332668/>, <https://onco.cc/trials/nct05482893/>, <https://onco.cc/trials/nct04140526/>, <https://onco.cc/trials/nct04083599/>, <https://onco.cc/trials/nct07054567/>, <https://onco.cc/trials/nct03228667/>, <https://onco.cc/trials/nct03407144/>, <https://onco.cc/trials/nct06099782/>, <https://onco.cc/trials/nct07098988/>, <https://onco.cc/trials/nct06797297/>, <https://onco.cc/trials/nct05970497/>, <https://onco.cc/trials/keynote-158/>, <https://onco.cc/trials/nct03611868/>, <https://onco.cc/trials/nct04752826/>, <https://onco.cc/trials/nct04895722/>, <https://onco.cc/trials/nct05081609/>, <https://onco.cc/trials/nct06731907/>, <https://onco.cc/trials/nct06784648/>, <https://onco.cc/trials/nct05789082/>, <https://onco.cc/trials/nct06699836/>, <https://onco.cc/trials/nct06284590/>, <https://onco.cc/trials/nct05320588/>, <https://onco.cc/trials/nct07255664/>, <https://onco.cc/trials/nct05086692/>, <https://onco.cc/trials/nct04701476/>, <https://onco.cc/trials/nct07807163/>, <https://onco.cc/trials/nct03897881/>, <https://onco.cc/trials/nct05797168/>, <https://onco.cc/trials/nct04585750/>, <https://onco.cc/trials/nct06644768/>, <https://onco.cc/trials/nct03785249/>, <https://onco.cc/trials/nct07452224/>, <https://onco.cc/trials/nct06265025/>, <https://onco.cc/trials/nct07221474/>, <https://onco.cc/trials/nct05585320/>, <https://onco.cc/trials/nct04787042/>, <https://onco.cc/trials/nct04920617/>, <https://onco.cc/trials/nct05620134/>, <https://onco.cc/trials/nct07622186/>, <https://onco.cc/trials/nct04675294/>, <https://onco.cc/trials/nct05440708/>, <https://onco.cc/trials/nct05877430/>, <https://onco.cc/trials/nct06162221/>, <https://onco.cc/trials/nct03526835/>, <https://onco.cc/trials/nct07264816/>, <https://onco.cc/trials/nct04736173/>, <https://onco.cc/trials/nct05144698/>, <https://onco.cc/trials/nct02861573/>, <https://onco.cc/trials/nct05394103/>, <https://onco.cc/trials/nct03647163/>, <https://onco.cc/trials/nct05805501/>, <https://onco.cc/trials/nct05318573/>, <https://onco.cc/trials/nct05816252/>, <https://onco.cc/trials/nct07287917/>, <https://onco.cc/trials/nct06307431/>, <https://onco.cc/trials/nct06961006/>, <https://onco.cc/trials/nct06228326/>, <https://onco.cc/trials/nct06205706/>, <https://onco.cc/trials/nct07122687/>, <https://onco.cc/trials/nct07020221/>, <https://onco.cc/trials/nct06137144/>, <https://onco.cc/trials/nct03836352/>, <https://onco.cc/trials/nct05128487/>, <https://onco.cc/trials/nct05217446/>, <https://onco.cc/trials/nct06843447/>, <https://onco.cc/trials/nct04675333/>, <https://onco.cc/trials/nct05438420/>, <https://onco.cc/trials/nct05824975/>, <https://onco.cc/trials/nct06047379/>, <https://onco.cc/trials/nct05186974/>, <https://onco.cc/trials/nct05903833/>, <https://onco.cc/trials/nct04198766/>, <https://onco.cc/trials/nct04977453/>, <https://onco.cc/trials/nct03476681/>, <https://onco.cc/trials/nct05309421/>, <https://onco.cc/trials/nct06428409/>, <https://onco.cc/trials/nct05117242/>, <https://onco.cc/trials/nct07223047/>, <https://onco.cc/trials/nct04130516/>, <https://onco.cc/trials/nct06483334/>, <https://onco.cc/trials/nct05120596/>, <https://onco.cc/trials/nct04956640/>, <https://onco.cc/trials/nct06393374/>, <https://onco.cc/trials/nct07486817/>, <https://onco.cc/trials/nct07158918/>, <https://onco.cc/trials/nct05565378/>, <https://onco.cc/trials/nct05609578/>, <https://onco.cc/trials/nct06623422/>, <https://onco.cc/trials/nct07815665/>, <https://onco.cc/trials/nct06293651/>, <https://onco.cc/trials/nct04305795/>, <https://onco.cc/trials/nct03725059/>, <https://onco.cc/trials/nct06795412/>, <https://onco.cc/trials/nct06731478/>, <https://onco.cc/trials/nct06246110/>, <https://onco.cc/trials/nct07197827/>, <https://onco.cc/trials/nct07720284/>, <https://onco.cc/trials/nct07276399/>, <https://onco.cc/trials/nct06469944/>, <https://onco.cc/trials/nct07232602/>, <https://onco.cc/trials/nct07415031/>, <https://onco.cc/trials/nct06901531/>, <https://onco.cc/trials/nct06249048/>, <https://onco.cc/trials/nct06942234/>, <https://onco.cc/trials/nct07475806/>, <https://onco.cc/trials/nct07710885/>, <https://onco.cc/trials/nct05224141/>, <https://onco.cc/trials/nct04626479/>, <https://onco.cc/trials/nct07252739/>, <https://onco.cc/trials/nct06157151/>, <https://onco.cc/trials/nct03547973/>, <https://onco.cc/trials/nct06312176/>, <https://onco.cc/trials/nct06764875/>, <https://onco.cc/trials/nct05405595/>, <https://onco.cc/trials/nct07302347/>, <https://onco.cc/trials/nct06008093/>, <https://onco.cc/trials/nct04585035/>, <https://onco.cc/trials/nct07469774/>, <https://onco.cc/trials/nct05687266/>, <https://onco.cc/trials/nct06151574/>, <https://onco.cc/trials/nct04262466/>, <https://onco.cc/trials/nct04521413/>, <https://onco.cc/trials/nct05945823/>, <https://onco.cc/trials/nct05329532/>, <https://onco.cc/trials/nct06119581/>, <https://onco.cc/trials/nct06966700/>, <https://onco.cc/trials/nct04121455/>, <https://onco.cc/trials/nct06305767/>, <https://onco.cc/trials/nct06116136/>, <https://onco.cc/trials/nct05562830/>, <https://onco.cc/trials/nct07566156/>, <https://onco.cc/trials/nct06797635/>, <https://onco.cc/trials/nct06877650/>, <https://onco.cc/trials/nct03485209/>, <https://onco.cc/trials/nct05642780/>, <https://onco.cc/trials/nct05609968/>, <https://onco.cc/trials/nct06385080/>, <https://onco.cc/trials/nct06549946/>, <https://onco.cc/trials/nct07644039/>, <https://onco.cc/trials/nct06545955/>, <https://onco.cc/trials/nct03505320/>, <https://onco.cc/trials/nct05319730/>, <https://onco.cc/trials/nct06772623/>, <https://onco.cc/trials/nct06041802/>, <https://onco.cc/trials/nct04225117/>, <https://onco.cc/trials/nct05732831/>, <https://onco.cc/trials/nct05669430/>, <https://onco.cc/trials/nct04241185/>, <https://onco.cc/trials/nct05899049/>, <https://onco.cc/trials/nct04938817/>, <https://onco.cc/trials/nct05101070/>, <https://onco.cc/trials/nct04976634/>, <https://onco.cc/trials/nct04895358/>, <https://onco.cc/trials/nct04626518/>, <https://onco.cc/trials/nct06112379/>, <https://onco.cc/trials/nct07315750/>, <https://onco.cc/trials/nct05761223/>, <https://onco.cc/trials/nct07679360/>, <https://onco.cc/trials/nct07639450/>, <https://onco.cc/trials/nct05173987/>, <https://onco.cc/trials/nct04041310/>, <https://onco.cc/trials/nct06875310/>, <https://onco.cc/trials/nct06016920/>, <https://onco.cc/trials/nct06780111/>, <https://onco.cc/trials/nct05911295/>, <https://onco.cc/trials/nct05410145/>, <https://onco.cc/trials/nct06225596/>, <https://onco.cc/trials/nct07751042/>, <https://onco.cc/trials/nct05533697/>, <https://onco.cc/trials/nct06868277/>, <https://onco.cc/trials/nct05438329/>, <https://onco.cc/trials/nct06978114/>, <https://onco.cc/trials/nct06788912/>, <https://onco.cc/trials/nct03711032/>, <https://onco.cc/trials/nct05852691/>, <https://onco.cc/trials/nct07730021/>, <https://onco.cc/trials/nct06962787/>, <https://onco.cc/trials/nct06618287/>, <https://onco.cc/trials/nct07811193/>, <https://onco.cc/trials/nct06472076/>, <https://onco.cc/trials/nct07287995/>, <https://onco.cc/trials/nct04561362/>, <https://onco.cc/trials/nct05239741/>, <https://onco.cc/trials/nct06493552/>, <https://onco.cc/trials/nct04879329/>, <https://onco.cc/trials/nct05053880/>, <https://onco.cc/trials/nct06556563/>, <https://onco.cc/trials/nct06939595/>, <https://onco.cc/trials/nct05845814/>, <https://onco.cc/trials/nct04380636/>, <https://onco.cc/trials/nct07286266/>, <https://onco.cc/trials/nct06841354/>, <https://onco.cc/trials/nct07749586/>, <https://onco.cc/trials/nct04592653/>, <https://onco.cc/trials/nct04634877/>, <https://onco.cc/trials/nct06890598/>, <https://onco.cc/trials/nct06634875/>, <https://onco.cc/trials/keynote-119/>, <https://onco.cc/trials/swog-s1418/>, <https://onco.cc/trials/neopact/>, <https://onco.cc/trials/c-trak-tn/>, <https://onco.cc/trials/impassion030/>, <https://onco.cc/trials/nct05093231/>, <https://onco.cc/trials/keynote-091/>, <https://onco.cc/trials/keynote-671/>, <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/trials/keynote-042/>, <https://onco.cc/trials/keynote-407/> ;
  onco:people <https://onco.cc/people/tasuku-honjo/>, <https://onco.cc/people/lajos-pusztai/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-189-nejm-2018/>, <https://onco.cc/key-papers/paper-keynote-564-nejm-2021/>, <https://onco.cc/key-papers/paper-keynote-355-nejm-2022/>, <https://onco.cc/key-papers/paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023/>, <https://onco.cc/key-papers/paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020/>, <https://onco.cc/key-papers/paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018/>, <https://onco.cc/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/>, <https://onco.cc/key-papers/paper-le-mmr-deficiency-science-2017/>, <https://onco.cc/key-papers/paper-moreira-lynch-syndrome-identification-jama-2012/> .